Phase 3 VALOR Trial Shows Brepocitinib Improves Outcomes in Dermatomyositis
As reported by GlobeNewsWire, results from the Phase 3 VALOR trial evaluating brepocitinib in adults with dermatomyositis have been published in the New England Journal of Medicine, marking a significant…